Modulation of expression of specific transcription factors involved in the bone microenvironment

Minerva Biotecnologica

Volumn 20, Issue 2, 2008, Pages 69-77

  Lambertini, E ^a   Penolazzi, L ^a   Tavanti, E ^a   Pocaterra, B ^a   Schincaglia, G P ^a   Torreggiani, E ^a   Franceschetti, T ^a   Vecchiatini, R ^a   Gambari, R ^a   Piva, R ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Estrogen; NF kappaB; NFATC transcription factors; Osteoclasts; Receptors

Indexed keywords

CIS ACTING ELEMENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN DECOY OLIGODEOXYNUCLEOTIDE; OLIGODEOXYNUCLEOTIDE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; TRANSCRIPTION FACTOR NFATC1 DECOY OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR RUNX2;

APOPTOSIS; BINDING AFFINITY; BONE ATROPHY; BONE TURNOVER; CELL DIFFERENTIATION; CONFERENCE PAPER; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; ENZYME REGULATION; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING;

EID: 48349131548     PISSN: 11204826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-55.
2. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406.
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
4. Karsenty G. Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 2006;4:341-8.
5. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289,1508-14.
6. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 999;190:1741-54.
7. Ross FP, Teitelbaum SL. αvβ3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005;208:88-105.
8. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD et al. Requirement for NF-kB in osteoclast and B-cell development. Genes Dev 1997;11:3482-96.
9. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-kB1 and NF-kB2. Nat Med 1997;3:1285-9.
10. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004;5:392-401.
11. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-9.
12. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K et al. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000;408:600-5.
13. Ozaki K, Takeda H, Iwahashi H, Kitano S, Hanazawa S. NF-kB inhibitors stimulate apoptosis of rabbit mature osteoclasts and inhibit bone resorption by these cells. FEBS Lett 1997;410:297-300.
14. Takeuchi T, Tsuboi T, Arai M, Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 2000;61:579-86.
15. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.
16. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153-64.
17. Romano MF, Lamberti A, Bisogni R, Tassone P, Pagnini D, Storti G et al. Enhancement of cytosine arabinoside-induced apoptosis in human myeloblastic leukemia cells by NF-kappa B/Rel-specific decoy oligodeoxynucleotides. Gene Ther 2000;7:1234-7.
18. Kajino S, Suganuma M, Teranishi F, Takahashi N, Tetsuka T, Ohara H et al. Evidence that de novo protein synthesis is dispensable for anti-apoptotic effects of NF-kappaB. Oncogene 2000;19:2233-9.
19. Qin JZ, Bacon P, Chaturvedi V, Nickoloff BJ. Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferongamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol 2001;117:898-907.
20. Bernard D, Quatannens B, Vandenbunder B, Abbadie C. Rel/NFkappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 2001;276:27322-8.
21. Cho-Chung YS, Park YG, Nesterova M, Lee YN, Cho YS. CRE-decoy oligonucleotide-inhibition of gene expression and tumor growth. Mol Cell Biochem 2000;212:29-34.
22. Piva R, Gambari R. Transcription factor decoy (TFD) in breast cancer research and treatment. Technol Cancer Res Treat 2002;1:405-16. 1196 L.
23. Cooper Jr JA, Parks JM, Carcelen R, Kahlon SS, Sheffield M, Culbreth R. Attenuation of interleukin-8 production by inhibiting nuclear factor-kappaB translocation using decoy oligonucleotides. Biochem Pharmacol 2000;59:605-13.
24. Kozlov IA, Kubareva EA, Ivanovskaya MG, Shabarova ZA. Design of new reagents on the base of DNA duplexes for irreversible inhibition of transcription factor NF-kappa B. Antisense Nucleic Acid Drug Dev 1997;7:279-89.
25. Vos IH, Govers R, Grone HJ, Kleij L, Schurink M, De Weger RA et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000; 14:815-22.
26. Bonham CA, Peng L, Liang X, Chen Z, Wang L, Ma L et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002;169:3382-91.
27. Quan N, Ho E, La W, Tsai YH, Bray T. Administration of NF-kappaB decoy inhibits pancreatic activation of NF-kappaB and prevents diabetogenesis by alloxan in mice. FASEB J 2001; 15:1616-8.
28. Papavassiliou AG. Transcription-factor-modulating agents: precision and selectivity in drug design. Mol Med Today 1998;4:358-66.
29. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y et al. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-9.
30. Bianchi N, Borgatti M, Gambari R. Gene silencing in thalassemia. Minerva Biotec 2008;20:51-5.
31. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A et al. In vivo transfection of the cis element "decoy" against the nuclear factor-kappa B binding site prevents myocardial infarction, Nat Med 1997;3:894-9.
32. Tomita N, Horiuchi M, Tomita S, Gibbons GH, Kim JY, Baran D et al. A novel strategy transcription factor decoy for E2F inhibits proliferation in mesangial cells in vitro. Am J Physiol 1998;27:F278-84.
33. Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K et al. In vivo transfection of NF-kB, decoy ODN suppressed the severity of rat collagen-induced arthritis as a gene therapy. Arthritis Rheum 1999;42:2535-42.
34. Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, Notake M et al. In vivo administration of a nuclear transcription factor-kappa B decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 2000;11:1244-52.
35. Tomita N, Morishita R, Tomita S, Gibbons GH, Zhang L, Horiuchi M et al. Transcription factor decoy for NF kappa B inhibits TNFalpha-induced cytokine and adhesion molecule expression in vivo. Gene Ther 2000;7:1326-32.
36. Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H et al. Inhibition of NF kappa B activation using a cis-element "decoy" of NF kappa B binding site reduces neointimal formation in a porcine balloon-injured coronary artery model. Gene Ther 2003;10:356-64.
37. Tomita N, Kim JY, Gibbons GH, Zhang L, Kaneda Y, Stahl RA et al. Gene therapy with E2F transcription factor decoy inhibits cell cycle progression in anti-Thy 1 glomerulonephritis. Int J Mol Med 2004;13:629-36.
38. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxy-nucleotides suppressing activity of nuclear factor kappa-B and ets transcription factors. Circulation 2004;109:132-8.
39. Weintraub SJ, Prater C, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992;358:259-61.
40. Nakamura H, Aoki M, Tamai K, Oishi M, Ogihara T, Kaneda Y et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther 2002;9:1221-9.
41. Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S et al. Intratumoral injection of oligonucleotides to the NF kappaB binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999;6:91-7.
42. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res 1996;16:61-9.
43. Griesenbach U, Cassady RL, Cain RJ, du Bois RM, Geddes DM, Alton EW. Cytoplasmic deposition of NFkappaB decoy oligonucleotides is insufficient to inhibit bleomycin-induced pulmonary inflammation. Gene Ther 2002;9:1109-15.
44. D'Acquisto F, Ialenti A, Ianaro A, Di Vaio R, Carnuccio R. Local administration of transcription factor decoy oligonucleotides to nuclear factor-kappaB prevents carrageenin-induced inflammation in rat hind paw. Gene Ther 2000;7:1731-7.
45. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A et al. In vivo transfection of cis element "decoy" against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 1997;3:894-9.
46. Kupatt C, Wichels R, Deiss M, Molnar A, Lebherz C, Raake P et al. Retroinfusion of NfkappaB decoy oligonucleotide extends cardioprotection achieved by CD18 inhibition in a preclinical study of myocardial ischemia and retroinfusion in pigs. Gene Ther 2002;9:518-26.
47. Sakaguchi T, Sawa Y, Fukushima N, Nishimura M, Ichikawa H, Kaneda Y et al. A novel strategy of decoy transfection against nuclear factor-kappaB in myocardial preservation. Ann Thorac Surg 2001;71:624-9.
48. Suzuki J, Morishita R, Amano J, Kaneda Y, Isobe M. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther 2000;7:1847-52.
49. Ueno, T, Sawa Y, Kitagawa-Sakakida S, Nishimura M, Morishita R, Kaneda Y et al. Nuclear factor kappaB decoy attenuates neuronal damage after global brain ischemia: a future strategy for brain protection during circulatory arrest. J Thorac Cardiovasc Surg 2001;122:720-7.
50. Penolazzi L, Lambertini E, Borgatti M, Piva R, Cozzani M, Giovannini I et al. Decoy oligodeoxynucleotides targeting NF-kappaB transcription factors: induction of apoptosis in human primary osteoclasts. Biochem Pharmacol 2003;66:1189-98.
51. Penolazzi L, Magri E, Lambertini E, Calò G, Cozzani M, Siciliani G et al. Local in vivo administration of a decoy oligonucleoticle targeting NF-kappaB induces apoptosis of osteoclasts after application of orthodontic forces to rat teeth. IntJ Mol Med 2006;18:807-11.
52. Monte MW, Pan M, Starbuck M, Gallo EM, Deng L III, Karsenty G et al. Calcineurin/NFAT signaling in Osteoblasts regulates bone mass developmental Cell 2006;10, 771-82.
53. Hogan PG, Chen L, Nardone J, Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003;17:2205-32.
54. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-9.
55. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signalling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901.
56. Kim Y, Sato K, Asagiri M, Morita I, Soma K, Takayanagi H. Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem 2005;280:32905-13.
57. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279: 45969-79.
58. Anusaksathien O, Laplace C, Li X, Ren Y, Peng L, Goldring SR et al. Tissue-specific and ubiquitous promoters direct the expression of alternatively spliced transcripts from the calcitonin receptor gene. J Biol Chem 2001;276:22663-74.
59. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83:170-9.
60. Koga T, Matsui Y, Asagiri M, Kodama T, de Crombrugghe B, Nakashima K et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med 2005;11:880-5.
61. Zhu L, Zaidi S, Moonga BS, Troen BR, Sun L. RANK-L induces the expression of NFATc1, but not of NFkB subunits during osteoclast formation. Bioch Bioph Res Comm 2004;326:131-5.
62. Kaminuma O, Deckert M, Elly C, Liu YC, Altman A. Vav-Rac1-mediated activation of the c-Jun N-terminal kinase/c-Jun/AP-1 pathway plays a major role in stimulation of the distal NFAT site in the interleukin-2 gene promoter, Mol Cell Biol 2001;21:3126-36.
63. Cozzani M, Giovannini I, Naccari R, Penolazzi L, Lambertini E, Borgatti M et al. Transcription Factor Decoy (TTD) as a novel approach for the control of osteoclastic resorption. Prog Orthod 2005;6:238-47.
64. Piva R, Penolazzi L, Lambertini E, Giordano S, Gambari R. Induction of apoptosis of human primary osteoclasts treated with a transcription factor decoy mimicking a promoter region of estrogen receptor alpha. Apoptosis 2005;10:1079-94.
65. Piva R, Penolazzi L, Zennaro M, Bianchini E, Magri E, Borgatti M et al. Induction of apoptosis of osteoclasts by targeting transcription factors with decoy molecules. Ann N Y Acad sci 2006;1091:509-16.
66. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89:747-54.
67. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-64.
68. Komori T. Regulation of skeletal development by the Runx family of transcription factors. J Cell Biochem 2005;95:445-53.
69. Stein GS, Lian JB, van Wijnen AJ, Stein JL, Montecino M, Javed A et al. Runx2 control of organization, assembly and activity of the regulatory machinery for skeletal gene expression. Oncogene 2004;23:4315-29.
70. Barski A, Frenkel B. ChIP Display: novel method for identification of genomic targets of transcription factors. Nucleic Acids Res 2004;32:e104.
71. Stock M, Schafer H, Fliegauf M, Otto F. Identification of novel genes of the bone-specific transcription factor Runx2. J Bone Miner Res 2004;19:959-72.
72. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Boderiner DL, Han L et al. Nongenotropic, sex-nonspecific signalling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 2001;104:1-20.
73. Zhou S, Zilberman Y, Wassermann K, Bain SD, Sadovsky Y, Gazit D. Estrogen modulates estrogen receptor alpha and beta expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. J Cell Biochem Suppl 2001;(Suppl 36):144-55.
74. Gohel A, McCarthy MB, Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology 1999;140:5339-47.
75. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835-9.
76. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
77. Green S, Chambon P. Nuclear receptors enhance our understanding of transcription regulation. Trends Genet 1988;4:309-14.
78. Komm BS, Terpening CM, Benz DJ, Graeme KA, Gallegos A, Korc M et al. Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells. Science 1988;241:81-4.
79. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC et al. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241:84-6.
80. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 2006;1068:173-9.
81. Kos M, Reid G, Denger S, Gannon F. Minireview: genomic organization of the human ERalpha gene promoter region. Mol Endocrinol 2001;15:2057-63.
82. Lambertini E, Penolazzi L, Giordano S, Del Serino L, Piva R. Expression of the human oestrogen receptor-α gene is regulated by promoter F in MG-63 osteoblastic cells. Biochem J 2003;372:831-9.
83. Lambertini E, Penolazzi L, Tavanti E, Schincaglia GP, Zennaro M, Gambari R et al. Human estrogen receptor alpha gene is a target of Runx2 transcription factor in osteoblasts. Exp Cell Res 2007;313:1548-60.
84. Tijsterman M, Ketting RF, Plasterk RHA. The genetics of RNA silencing. Annu Rev Genet 2002;36:489-19.
85. Denli AM, Hannon GJ. RNAi: an ever-growing puzzle. Trends Biochem Sci 2003;28:196-201.